Clinical Research Directory
Browse clinical research sites, groups, and studies.
Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer
Sponsor: Vanderbilt University Medical Center
Summary
The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT). The primary objective is to reduce the number of units of allogenic blood transfusion in locally advanced kidney cancer (≥ cT2). Secondary objectives include reduction in perioperative complications, assessment of recurrence free-survival and improving overall survival.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
240
Start Date
2021-07-23
Completion Date
2027-06-15
Last Updated
2025-11-12
Healthy Volunteers
No
Conditions
Interventions
Blood Sparing Protocol
Acute Normovolemic Hemodilution, Cell Saver, and/or Veno-venous Bypass
Standard Blood Replacement
Allogenic blood transfusion as determined intra-operatively
Locations (3)
H. Lee Moffitt Cancer Center
Tampa, Florida, United States
Winship Cancer Institute at Emory University
Atlanta, Georgia, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States